U.S. Sterile Injectables Market, by Molecule Type (Large Molecule and Small Molecule), by Drug Type (Monoclonal Antibody (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulin’s, Blood Factors, Peptide Antibiotics, and Others), by Therapeutic Application (Cancer, Metabolic Diseases, Cardiovascular Diseases, Central Nervous System Disorder, Infectious Diseases, Musculoskeletal Disorders, and Others), by Route of Administration (Subcutaneous (SC), Intravenous (IV), Intramuscular (IM), and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) is estimated to be valued at US$ 131.8 Billion in 2022 and is expected to exhibit a CAGR of 9.3% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key players operating in the market are focusing on receiving product approvals from regulatory authorities and this is expected to drive the market growth over the forecast period.
For instance, in April 2021, the U.S Food and Drug Administration approved Gilead Trodelvy for the treatment of unresectable locally advanced or metastatic triple negative breast cancer.
Moreover, in October 2021, Adamis Pharmaceuticals Corporation, is a speciality pharmaceutical company focused on developing and commercializing products in the therapeutic area of respiratory disease, allergies, oncology and immunology received the U.S Food and Drug Application (FDA) for ZIMHI (naloxone HCL Injection, USP) 5mg/0.5 ml product. Moreover, ZIMHI is a high dose naloxone injection product FDA approved for use in the treatment of opioid overdose.
U.S Sterile Injectables Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 has had a positive impact on sterile injectables market as lot of people got infected with COVID-19 infection and most of infected people needed to get admitted to the hospitals, while on the other hand most of U.S population have got vaccinated to stop the spread of virus. Moreover, certain players of the market are collaborating for the manufacturing of COVID-19 vaccine.
For instance, in November 2021, Greenlight biosciences and Samsung biologics announced collaboration to build capacity for messenger RNA COVID-19 vaccine manufacturing.
Browse 16 Market Data Tables and 36 Figures spread through 154 Pages and in-depth TOC on “Sterile Injectables Market”- U.S. Forecast to 2030, by Molecule Type (Large Molecule and Small Molecule), by Drug Type (Monoclonal Antibody (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulin’s, Blood Factors, Peptide Antibiotics, and Others), by Therapeutic Application (Cancer, Metabolic Diseases, Cardiovascular Diseases, Central Nervous System Disorder, Infectious Diseases, Musculoskeletal Disorders, and Others), by Route of Administration (Subcutaneous (SC), Intravenous (IV), Intramuscular (IM), and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies).
To know the latest trends and insights prevalent in the U.S Sterile Injectables Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/us-sterile-injectables-market-4961
Key players operating in the market are focusing on adoption of inorganic growth strategies such as mergers, collaborations, partnerships, and acquisitions, in order to strengthen their position in the global market. For instance, in September 2021, Hikma Pharmaceuticals, plc. Is a British multinational pharmaceutical company with headquarters in London UK strengthens the U.S. injectables business through acquisition of Custopharm.
Key Takeaways of the U.S Sterile Injectables Market:
The U.S sterile injectables market is expected to exhibit a CAGR of 9.3 % over the forecast period, owing to rising launches and regulatory approvals of products and manufacturing sites. For instance, Xellia Pharmaceuticals, a speciality pharmaceutical company focusing on providing important anti-invectives treatments against serious and often life-threatening infections, received approval from the U.S. Food and Drug Administration (FDA) allowing the company to commence Injectables manufacturing site in Cleveland, Ohio.
Among molecule type, large molecule segment is expected to account for largest market share during the forecast period, owing to increase in cancer population. For instance, according to American Cancer Society there were about 1.9 million cancer diagnosed cases in 2021.
Key players operating in the U.S. sterile injectables market include Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services, Inc., Gilead Sciences, Inc., JHP Pharmaceuticals, Pfizer Inc., Fresenius Kabi Ag, CordenPharma, and Hikma Pharmaceuticals PLC.
